Launch Therapeutics
- Company typePrivate
- Founded2022
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Launch Therapeutics firmographics
Firmographics- Name
- Launch Therapeutics
- Legal name
- Launch Therapeutics, Inc.
- Website
- https://launchtx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Launch Therapeutics industry classification
Industry- Product category
- Clinical Development Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Launch Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Launch Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Clinical Co-Development Services: Launch Tx provides operational execution and management of clinical trials for pharmaceutical partners. They receive payment for performing services in accordance with co-development agreements. Partners gain access to strategic guidance, operational resources, and development funding.
- Development Financing: Abingworth (backed by Carlyle) provides development funding to offset program costs for partnered companies. In return, Abingworth receives fixed payments upon regulatory approval and success payments based on sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Launch Therapeutics product offering
Product offeringCore offering
Launch Therapeutics provides clinical co-development services to pharmaceutical and biotechnology companies, taking the lead role in operational execution and management of late-stage (Phase 3) clinical trials. The company pairs deep drug development, medical, regulatory, and clinical operations expertise with development financing from its backers Carlyle and Abingworth, structuring co-development agreements in which partners retain manufacturing, regulatory interactions, and commercialization responsibilities.
Product overview
Launch Therapeutics is a clinical development company offering innovative co-development models that combine access to capital with deep drug development, medical, clinical operations, regulatory, and commercialization expertise. The company provides clinical co-development services to pharmaceutical and biotech companies through various models including clinical co-development (CCD) investments, risk financing, and full in-licensing arrangements. Key co-development partnerships include the TEV-'248 ICS-SABA asthma rescue inhaler program with Teva, the TRODELVY NSCLC program with Gilead, and the upacicalcet Phase 3 program with Pathalys Pharma. Founded in 2022 and backed by Carlyle and Abingworth, Launch Tx focuses on late-stage clinical assets, having supported 6 Phase III studies across 955+ sites in 85+ countries with 4,200+ patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Co-Development Services Operational execution and management of late-stage (Phase 3) clinical trials for pharmaceutical and biotech partners, combining strategic guidance, clinical development plan validation, feasibility assessment, and access to development capital under custom co-development agreements.
- TEV-'248 (ICS/SABA) Asthma Rescue Inhaler Program Co-development program with Teva Pharmaceutical Industries for a dual-action ICS/SABA (fluticasone propionate and albuterol sulfate) multidose dry powder rescue inhaler for the reduction and prevention of asthma exacerbations, with Launch Tx leading operational execution and management of the clinical trials.
- TRODELVY (sacituzumab govitecan-hziy) NSCLC Program Clinical collaboration program with Gilead Sciences supporting select clinical studies of TRODELVY, a first-in-class Trop-2-directed antibody-drug conjugate, in non-small cell lung cancer, governed by a Joint Steering Committee with development leadership from Launch Tx.
- Upacicalcet (PLS240) Phase 3 Program
Quantifiable outcome
- 6 Phase III studies completed or underway
- +3 more outcomes
Companies that use Launch Therapeutics
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Launch Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Launch Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Teva Pharmaceutical IndustriescoreClinical collaboration agreement for TEV-'248 (ICS/SABA) dual-action asthma rescue inhaler program. Launch Tx has lead role in operational execution and management of planned clinical trials. Investors committed up to $150 million in funding to offset program costs. Teva retains primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. Joint Steering Committee established with executive leadership from both organizations.
- Gilead SciencescoreClinical collaboration agreement establishing Joint Steering Committee to support select clinical studies of TRODELVY® (sacituzumab govitecan-hziy) within non-small cell lung cancer. Investors committed up to $210 million in funding to support clinical studies. Gilead retains full rights to Trodelvy and if development is successful, Abingworth would receive fixed payment upon regulatory approval and royalty payments based on U.S. net sales.
- Pathalys PharmacoreStrategic collaboration to advance upacicalcet (PLS240) through pivotal Phase 3 studies for treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Investors committed $150 million through secured product financing and equity to support Phase 3 trials, registration efforts, and pre-commercialization activities. Launch Tx has lead role in operational execution and management of clinical trials.
- OptheacorePartnership to advance OPT-302, a promising therapy for wet age-related macular degeneration (wet AMD). Opthea secured up to US$170 million in non-dilutive financing to support the development program.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Launch Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Medpace Holdings: Medpace is a mid-to-large CRO focused on full-service clinical development for small and mid-sized biopharma. Its operational model overlaps significantly with the trial execution work Launch Tx performs for partners.
- PPD (Thermo Fisher Scientific): PPD is a major global CRO providing clinical development services to pharma and biotech, now owned by Thermo Fisher. It is a comparable clinical operations services provider with similar late-stage trial execution capabilities, though structured as a traditional CRO rather than a co-development financier.
- IQVIA: IQVIA is one of the world's largest CROs and clinical development services providers. It offers the operational execution and clinical trial management services that Launch Tx either delivers directly or orchestrates through vendors, making it a broad incumbent against which Launch Tx positions itself as a more focused, capital-aligned alternative.
- Parexel International: Parexel is a global CRO providing clinical trial design, execution, and regulatory services. It is a broad incumbent serving the same pharmaceutical and biotech clients that Launch Tx targets.
- ICON plc: ICON is one of the largest global CROs, offering end-to-end clinical development services across all phases. It competes with Launch Tx for clinical operations work and represents the incumbent services model that Launch Tx's co-development approach seeks to disrupt.
- Charles River Laboratories: Charles River provides early-stage and preclinical CRO services, and through its broader portfolio also competes for late-stage clinical work. It is an established life-sciences services incumbent with comparable customers.
Direct peers
- HealthCare Royalty Partners: HCR is a healthcare-focused royalty and structured financing firm that provides capital against late-stage development and commercial assets. It competes with Launch Tx/Abingworth in sourcing structured development financing deals against pharma and biotech assets.
- NovaQuest: NovaQuest is a clinical co-development financing firm that partners with biotech and pharma to fund late-stage clinical development in exchange for milestones and royalties. It is one of the longest-standing players in the same asset-financing and co-development niche as Launch Tx, with comparable deal structures.
- SFJ Pharmaceuticals: SFJ is the closest direct peer: a clinical co-development financing company structured similarly to Launch Tx, with a model of providing development capital and operational support in exchange for milestone and royalty payments. Launch Tx's President/COO (Jonathan DeBenedetto) and several board members came directly from SFJ, and the business models are essentially identical.
Others
- Abingworth: Abingworth is Launch Tx's sister/parent life-sciences investment firm and the source of all development financing for its co-development deals. It is thematically the same investment thesis but operates as the financial capital provider, whereas Launch Tx is the operational execution vehicle.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Launch Therapeutics social profiles
Digital presenceLaunch Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Launch Therapeutics leadership team
Management profileNumber of profiles
Profiles12 records
Launch Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Launch Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Launch Therapeutics
What does Launch Therapeutics do?
Launch Therapeutics provides clinical co-development services to pharmaceutical and biotechnology companies, taking the lead role in operational execution and management of late-stage (Phase 3) clinical trials. The company pairs deep drug development, medical, regulatory, and clinical operations expertise with development financing from its backers Carlyle and Abingworth, structuring co-development agreements in which partners retain manufacturing, regulatory interactions, and commercialization responsibilities.
Is Launch Therapeutics a public or private company?
Launch Therapeutics is a private company. It is classified as private equity controlled and is currently operating.
When was Launch Therapeutics founded?
Launch Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Launch Therapeutics based?
Launch Therapeutics is headquartered in Boston, United States, in the North America region.
How does Launch Therapeutics make money?
Two revenue lines are on record. Clinical Co-Development Services are the primary driver. The others are development Financing.
Who are Launch Therapeutics's main competitors?
Broad incumbents on record are Medpace Holdings, PPD (Thermo Fisher Scientific), IQVIA, Parexel International, ICON plc and Charles River Laboratories. Direct peers are HealthCare Royalty Partners, NovaQuest and SFJ Pharmaceuticals. Abingworth is listed as an others.
Does Launch Therapeutics have an API?
No public API is recorded for Launch Therapeutics.
What industry is Launch Therapeutics in?
Launch Therapeutics's product category is Clinical Development Services. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 5417 and its SIC code is 8731.